BofA lowered the firm’s price target on Alkermes (ALKS) to $33 from $35 and keeps a Neutral rating on the shares. The company reported a Q2 beat but issued few pipeline updates, the analyst tells investors in a research note. The firm left its out-year estimates unchanged, saying it does not see the Q2 strength carrying into 2026 and beyond given the growth trajectory of Alkermes’ key brands remains unchanged.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ALKS:
- Alkermes’s Strong Financial Performance and Promising Pipeline Drive Buy Rating
- Alkermes’ Strong Q2 2025 Performance and Future Growth Potential Justify Buy Rating
- Alkermes reports Q2 EPS 52c, consensus 38c
- Alkermes plc (ALKS) Q2 Earnings Cheat Sheet
- Alkermes Drug Update: Hold Rating Amid Positive Sleep Test Results and Cataplexy Concerns